Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612000535875
Ethics application status
Approved
Date submitted
3/05/2012
Date registered
21/05/2012
Date last updated
19/10/2016
Type of registration
Prospectively registered

Titles & IDs
Public title
MGMT Gene Therapy and Chemotherapy for the treatment of Childhood Brain Tumours
Scientific title
In paediatric patients with high risk brain tumours, is it safe and feasible to infuse autologous Peripheral Blood Stem Cells transduced with a mutant MGMT Gene?
Secondary ID [1] 280425 0
NIL
Universal Trial Number (UTN)
U1111-1128-1371
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Childhood Brain Tumours 286392 0
Condition category
Condition code
Cancer 286643 286643 0 0
Brain

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
1. Participants will be given a single dose of BCNU (600 mg/m^2, IV infusion) 48 to 56 hours before infusion of gene modified bone marrow stem cells. Patients who have had prior craniospinal radiotherapy will not receive this BCNU dose, but will be given Busulphan at a dosage of 4 mg/kg IV by 3 hour infusion (once daily for two days), finishing two days prior to the infusion of cells.
2. O6-Benzylguanine (O6BG) in combination with Temozolomide (TMZ) will be given as further cycles of chemotherapy for a maximum of 13 cycles, starting at a minimum of 21 days post infusion of gene modified cells, (provided there has been haematologic recovery and resolution of non-haematologic toxicities) as follows: Post-infusion cycle 1: 120 mg/m^2 O6BG Intravenously over 60 minutes for 5 days, and 75 mg/m^2/day TMZ orally, given 30 minutes after the end of each day's O6BG infusion. Dose escalation of the TMZ dose will occur in individual patients provided no Dose LimitingToxicity is observed in two successive cycles: as follows: Cycles 3 - 13 : Level 1 : TMZ 100 mg/m^2/day orally for 5 days, Level 2: TMZ 133 mg/M^2/day orally for 5 days, Level 3: TMZ 175mg/m^2/day orally for 5 days, Level 4: TMZ 235 mg/m^2/day orally for 5 days. Each cycle of chemotherapy will be given at a minimum of 21 days from the beginning of the previous cycle, provided there has been haematological recovery and resolution of non-haematologic toxicities.
3.Bone marrow stem cells gene-modified with a mutant drug resistance gene (MGMT) will be intravenously infused over 20 - 30 minutes, following completion of conditioning chemotherapy with O6BG and Temozolomide. Target dose minimum of 2 x 10^6 CD34+ cells.

Intervention code [1] 284782 0
Treatment: Drugs
Intervention code [2] 284783 0
Treatment: Other
Comparator / control treatment
There is no control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 287047 0
Safety and feasibility of the infusion of autologous Peripheral Blood Stem Cells, gene-modified with a mutant form of MGMT (designated MGMT(P140K), into paediatric patients with high risk brain tumours.
Safety will be assessed by documentation of toxicities graded according to the Common Terminology Criteria for Adverse Events (CTCAE). Feasibility will be assessed be documentation of the PBSC harvest yield, deliverable dose of gene-modified cells for infusion, measurement of engraftment of gene-modified cells.
Timepoint [1] 287047 0
Safety in relation to the chemotherapy component of the trial will be assessed following each cycle of chemotherapy given, and prior to any subsequent cycle, i.e. every 4 weeks until the end of chemotherapy treatment (up to 13 months), then monthly for the next 12 months, 3 monthly for 2 years, then 6 monthly for 2 years (5 yr timepoint) and annual assessment lifelong thereafter.
Feasability will be assessed at the time of cell infusion and then monthly until the end of chemotherapy.
Secondary outcome [1] 297268 0
To determine the:
1. efficiency of gene transfer and
2. the ability to selectively expand MGMT(P140K) expressing bone marrow cells with successive cycles of O6BG and Temozolomide treatment in paediatric patients with high risk brain tumours.
Timepoint [1] 297268 0
Gene transfer efficiency will be assessed using quantitative Polymerase-Chain-reactin (Q-PCR) of DNA extracted from gene-modified cells at the time of infusion.
Selective expansion of gene-modified cells will be assessed monthly by Q-PCR and antibody labelling of blood cells monthly prior to each chemotherapy cycle (up to 13 months)
Secondary outcome [2] 297269 0
To determine whether MGMT(P140K) expression affords the bone marrow protection from the toxic effects of chemotherapy, thus ameliorating toxicities and/or facilitating increased chemotherapy dose intensity in paediatric patients with high risk brain tumours. Tumour responses will be documented
Timepoint [2] 297269 0
Toxicities to chemotherapy will be documented following each cheomtherapy cycle (up to 13 cycles) according to CTCAE grading criteria.
Ability to dose escalate will be documented following criteria set out in the clinical protocol throughout the period during which chemotherapy is given.
Tumour responses will be documented by MRI scan prior to every second cycle of chemotherapy (ie pre-cylces 3,5,7,9,11,13) and then at the completion of chemotherapy.

Eligibility
Key inclusion criteria
1. Patient diagnosed with one of the following:
a) High grade glioma which has progessed or recurred following standard therapy
b) Medulloblastoma which has recurred following conventional therapy
c) Ependymoma which has recurred following maximal safe surgical resection and radiotherapy, and where maximal safe re-section and re-irradiation has been undertaken or considered not appropriate
d) Atypical teratoid/rhabdoid tumour which has recurred
e) Low grade glioma which has recurred
f) Brainstem glioma of diffuse pontine type

2. Life expectancy greater than or equal to 8 weeks
3. No severe uncontrolled infection
4. Performance status :
a) Karnofsky score > or equal to 50% (patient over 10 years old) OR
b) Lansky score > or equal to 50% (patient under/equal 10 years old)
5. Patient has adequate bone marrow function
6. Signed Informed Consent
Minimum age
1 Years
Maximum age
21 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Uncontrolled infection
2. Malignant infiltration of the bone marrow or any other site outside the central nervous system

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/06/2012
Actual
1/08/2012
Date of last participant enrolment
Anticipated
Actual
11/06/2015
Date of last data collection
Anticipated
Actual
19/01/2016
Sample size
Target
12
Accrual to date
Final
8
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 285182 0
Charities/Societies/Foundations
Name [1] 285182 0
The Kids' Cancer Project (formerly Oncology Children's Foundation)
Country [1] 285182 0
Australia
Funding source category [2] 285183 0
Charities/Societies/Foundations
Name [2] 285183 0
Sporting Chance Cancer Foundation
Country [2] 285183 0
Australia
Funding source category [3] 285184 0
Government body
Name [3] 285184 0
Department of Innovation, Industry Science and Research
Country [3] 285184 0
Australia
Primary sponsor type
Hospital
Name
The Sydney Children's Hospital Network
Address
The Children's Hospital at Westmead
Cnr Hawkesbury Rd and Hainsworth St
Locked Bag 4001
Westmead NSW 2145
Country
Australia
Secondary sponsor category [1] 284050 0
None
Name [1] 284050 0
Address [1] 284050 0
Country [1] 284050 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 287191 0
Sydney Children's Hospital Network Human Research Ethics Committee
Ethics committee address [1] 287191 0
Ethics committee country [1] 287191 0
Australia
Date submitted for ethics approval [1] 287191 0
Approval date [1] 287191 0
28/02/2011
Ethics approval number [1] 287191 0
08/CHW/22

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 34126 0
Prof Ian Alexander
Address 34126 0
Gene Therapy Research Unit,
The Children's Hospital at Westmead
Locked Bag 4001
Westmead
NSW 2145
Country 34126 0
Australia
Phone 34126 0
+ 612 9845 3071
Fax 34126 0
Email 34126 0
[email protected]
Contact person for public queries
Name 17373 0
Dr Geoff McCowage
Address 17373 0
Senior Staff Specialist
Oncology Unit
The Children's Hospital at Westmead
Locked Bag 4001
Westmead NSW 2145
Country 17373 0
Australia
Phone 17373 0
+61 2 98452141
Fax 17373 0
Email 17373 0
[email protected]
Contact person for scientific queries
Name 8301 0
Professor Ian Alexander
Address 8301 0
Professor in Paediatrics and Molecular Medicine
Head, Gene Therapy Research Unit
The Children's Hospital at Westmead
Locked Bag 4001
Westmead NSW 2145
Country 8301 0
Australia
Phone 8301 0
+61 2 98453071
Fax 8301 0
Email 8301 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
Dimensions AIMolecular profiling of childhood cancer: Biomarkers and novel therapies2014https://doi.org/10.1016/j.bbacli.2014.06.003
EmbaseClinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors.2018https://dx.doi.org/10.1089/hum.2017.235
N.B. These documents automatically identified may not have been verified by the study sponsor.